Mylan (MYL) Suit Against FDA Over Hear Drug Dismissed - Bloomberg
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan, Inc. (NASDAQ: MYL) saw a little volume move higher following headlines that its suit against the FDA over a generic heart drug was dismissed, according to Bloomberg headlines.
Shares are down 1.4 percent on the session, but off of lows.
Shares are down 1.4 percent on the session, but off of lows.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- ASLAN Pharmaceuticals (ASLN) Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
- UBS faces new lawsuit by Appaloosa over Credit Suisse $17 billion bond wipeout
Create E-mail Alert Related Categories
FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
